Livagen: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 28 de agosto de 2026

Livagen is a short synthetic tetrapeptide (sequence Lys-Glu-Asp-Ala, KEDA; formula C18H31N5O9, ~461.47 g/mol) belonging to the family of short peptide bioregulators described by Khavinson's group. For research use, it has been explored as a modulator of transcriptional activity and of chromatin condensation in cell models. The available evidence is limited and comes mostly from a single research group.

Livagen is a synthetic short-chain tetrapeptide whose sequence is Lysine-Glutamic-Aspartic-Alanine (Lys-Glu-Asp-Ala), abbreviated as KEDA. Its molecular formula is C18H31N5O9 and its molecular weight is around 461.47 g/mol. It does not have a single CAS number consolidated in the public databases, which is common for this class of compounds. It falls within the family of the so-called "short peptide bioregulators," a group of di-, tri-, and tetrapeptides developed and studied mainly by the group of Vladimir Khavinson and collaborators in Saint Petersburg. Livagen is frequently described as the synthetic peptide analog conceptually associated with liver extract (hence its name, in reference to the liver), within the same design rationale as other peptides in this series oriented toward different tissues.

From a structural standpoint, Livagen is a very small linear peptide, without disulfide bridges or complex modifications. Its reduced size distinguishes it from large peptide hormones and from proteins: short bioregulators like this are postulated as minimal fragments capable of interacting with nucleic acids and with the machinery of gene regulation. The central mechanistic hypothesis proposed by its researchers is that these tetrapeptides can bind selectively to specific DNA sequences in the groove of the double helix and to chromatin-associated proteins, thus modulating the compaction state of the genetic material and, consequently, the accessibility of certain genes to transcription. In the specific case of Livagen, the most cited experimental work has focused on its capacity to induce the decondensation of chromatin (heterochromatin) in lymphocytes, in particular in cells from elderly donors, where chromatin tends to be more condensed and transcriptionally silenced. In those in vitro models, an apparent reactivation of previously inactive regions has been observed, including the activation of ribosomal genes and the appearance of nucleoli, which is interpreted as an increase in cellular synthetic activity.

The mechanism of action, therefore, is described as epigenetic in a broad sense: it is not proposed that Livagen acts as a classic transcription factor or as a surface receptor agonist, but rather as a small ligand that physically interacts with chromatin to derepress gene expression. It has been suggested that affinity for certain dinucleotides or DNA motifs could confer a degree of tissue selectivity to the different peptides of the series, although this fine selectivity remains a matter of debate and is not firmly established by independent methods. It is important to emphasize that much of this conceptual framework comes from a relatively homogeneous body of work concentrated in a single research group, and that independent large-scale replication, as well as controlled clinical studies, are scarce or nonexistent.

As for the documented research applications, Livagen has been used almost exclusively in preclinical and laboratory contexts. The lines explored include: studies of chromatin biology and cellular aging, where it is used as a tool to attempt to reverse the condensation associated with lymphocyte senescence; models of regulation of ribosomal gene expression and nucleolar activity; and geroprotective or "anti-aging" work at the cellular level, in line with the group's general hypothesis that short bioregulators can restore gene expression patterns characteristic of young tissues. Because of its name and classification, it has also been discussed in the context of liver function, although the specific and solid evidence supporting concrete hepatic effects in well-controlled animal models is markedly limited. Any reading of these applications must be made with the understanding that this is early scientific exploration and not established indications.

Regarding the level of evidence, honesty requires being explicit: Livagen is a compound that is poorly characterized in the independent biomedical literature. Most of the available data comes from a single research environment, relying mainly on in vitro experiments and on a mechanistic model that, while coherent and published, does not have broad third-party validation or clinical trials to support a therapeutic use. There is no regulatory approval of Livagen as a drug by the major agencies, and no medical application should be inferred from this information. Its current value is that of a molecule of interest for basic research in epigenetics, biogerontology, and peptide biology, useful as an experimental probe for those studying the relationship between short peptides and chromatin regulation.

In summary, Livagen (KEDA) is a tetrapeptide from Khavinson's series of short bioregulators, proposed as a modulator of chromatin decondensation and transcriptional reactivation in cell models, with special attention to the liver because of its name and to aged lymphocytes because of its more frequent experimental use. It is offered strictly for research. The scientific community has limited data that are mostly not independently replicated, so conclusions about its efficacy and mechanism should be treated as preliminary and subject to additional verification.